S1E18 Automating Nanoparticle Characterization | David Freedman
David Freedman, co-founder and COO of NanoView Biosciences, explains how his background in electrical engineering and automation led to the development of the EXOView platform for characterizing exosome nanoparticles. He details the transition from academic research at Boston University to founding a startup, emphasizing the critical role of the NSF I-Corps program in validating the technology by getting "outside the building" to interview potential users. Freedman describes the EXOView instrument's automated workflow, which uses specialized silicon-glass chips and multispectral imaging to detect nanoparticles for applications in cancer diagnostics and viral detection.